Stockholm, Sweden, 3 February 2022
AnaCardio raises SEK 33 million for development of a novel therapy for heart failure
AnaCardio today announced the completion of a fundrasing round of 33 MSEK. The funds will be used to progress clinical development of its lead asset in heart failure. The capital injection is comprised of a convertible loan granted by Karolinska Development AB, LLD Nybohov Invest AB and Fredrik and AnnHelene Ljungström.
“We are pleased that these prominent investors want to continue supporting AnaCardio on its journey to improve the treatment options for heart failure patients. With this capital injection we are on-track to progress with our clinical plans for our lead asset AC01” says Patrik Strömberg, CEO.
About AnaCardio
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.
For further information, please contact
Patrik Strömberg, CEO
Telephone: +46 704 156 159
E-mail: Patrik.stromberg@anacardio.com
Link to PDF: https://anacardio.com/wp-content/uploads/2022/11/AnaCardio-raises-33-million-SEK_2022-02-03.pdf
